Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2-methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-24- dione (rosiglitazone) or a pharmaceutically acceptable salt thereof and a sub-maximal amount of glimepiride. The composition is intended for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in mammals. The invention also relates to the use of the aforementioned pharmaceutical composition.

In the present invention there is described a pharmaceutical composition containing 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione that means the compound of the general formula (I) or a pharmaceutically acceptable derivative thereof submaximal amount of composition for support of insulin secretion being selected from the group consisting of glibenclamide glipizide gliclazide and glimepiride and a pharmaceutically acceptable carrier. There is also described ...

In the present invention there is disclosed a pharmaceutical combination containing 2 to 8 mg of 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidine-24-dione (compound of the general formula I) or a tautomeric form and/or pharmaceutically acceptable derivative thereof and sulfonylurea wherein the sulfonylurea is represented by glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. There is also disclosed the use of the above-described combination in a pharmaceutica...

Pharmaceutical composition comprises 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 24-dione i. a. rosiglitazone in the form of a free base or a tautomeric form thereof and/or in the form of a pharmaceutically acceptable derivative and a sulphonylurea preferably glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. Also disclosed is the use of 2 to 8 mg of rosiglitazone and a sulphonylurea for the manufacture of a medicament for the treatment of...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue) to a mammal in need thereof. 2...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal with positive effect by glycemic control without observable unfavourable effects which method comprises administering 2 to 12 mg daily 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-24-dione (Compound I) or a pharmaceutically acceptable salt thereof and sulfonyl urea. 2. A method according to Claim 1 wherein the c is glibenclamide glipizide gliclazide glimepiride tola...